These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
35. Immunization against Pseudomonas aeruginosa: the effects of serotype and virulence in mouse protection tests. Markman B; Fall-Persson M; Salenstedt CR J Biol Stand; 1982 Oct; 10(4):319-28. PubMed ID: 6818231 [No Abstract] [Full Text] [Related]
36. [Use of Pseudomonas aeruginosa multicomponent vaccine in patients with intractable lower respiratory tract infection associated with diffuse panbronchiolitis]. Yoshimura K; Tachibana A; Nakatani T; Chonabayashi N; Nakamori Y; Nakata K; Tanimoto H Nihon Kyobu Shikkan Gakkai Zasshi; 1986 Jun; 24(6):625-32. PubMed ID: 3095578 [No Abstract] [Full Text] [Related]
37. Current status of Pseudomonas aeruginosa vaccine. Michelim L; Medeiros GS; Zavascki AP Curr Pharm Biotechnol; 2013; 14(11):951-9. PubMed ID: 24372247 [TBL] [Abstract][Full Text] [Related]
38. Roles of exoenzymes and exotoxin in the pathogenicity of Pseudomonas aeruginosa and the development of a new vaccine. Homma JY Jpn J Exp Med; 1980 Jun; 50(3):149-65. PubMed ID: 6776324 [No Abstract] [Full Text] [Related]
39. Experimental immunization with attenuated mutants of Pseudomonas aeruginosa. Syeklocha D Can J Microbiol; 1973 May; 19(5):573-80. PubMed ID: 4196781 [No Abstract] [Full Text] [Related]
40. [Combined Staphylococcus-Proteus-Pseudomonas vaccine. II. The toxicity of the vaccine in "chronic" experiments and its ability to protect animals against Proteus and Staphylococcus infections]. Kreĭnin LS; Egorova NB; Stanislavskiĭ ES; Kaverina KG; Levina LA Zh Mikrobiol Epidemiol Immunobiol; 1983 May; (5):87-92. PubMed ID: 6410625 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]